Spruce Biosciences develops therapies for neurological disorders, led by an enzyme replacement therapy for a rare genetic brain disease. SPRB reports earnings on Mon, Nov 9, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Prices, price targets and earnings estimates for SPRB are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in SPRB in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SPRB is in one of them and how their past SPRB trades turned out.
Spruce Biosciences is a biopharmaceutical company that develops therapies for neurological disorders. Its lead product candidate, TA-ERT, is an enzyme replacement therapy under development for MPS IIIB, a rare genetic disease that causes progressive brain damage and has no approved treatments. The therapy is designed to be delivered directly into the central nervous system, and its intended customers are patients with the disease and the clinicians who treat them. The company is based in South San Francisco, California.
